October 16, 2023 04:02 PM EDTUpdated 04:28 PM
Pharma
FDA+

Bris­tol My­ers scores an­oth­er Op­di­vo ap­proval, as Mer­ck con­verts AA to full ap­proval for Keytru­da in MCC

Lia DeGroot

Bris­tol My­ers Squibb on Fri­day nabbed an­oth­er ap­proval for its block­buster can­cer treat­ment Op­di­vo.

The drug was ap­proved to treat pa­tients …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Roche’s Parkin­son’s drug flunks sec­ond mid-stage tri­al

David Ep­stein gets $140M for Ot­ti­mo's bi­func­tion­al take on hot PD-1xVEGF field

Sang­amo strikes an­oth­er brain-tar­get­ing AAV part­ner­ship, this time with Astel­las

Bris­tol My­ers pays $100M up­front to col­lab­o­rate with Leqem­bi orig­i­na­tor in Alzheimer's

A service from the Financial Times